PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33002553-7	2020	CONCLUSION: In patients with T2DM and symptomatic CAD, the addition of Vildagliptin to ongoing metformin showed better glycemic control, lower inflammatory markers (IL-1beta and hsCRP), higher protective markers (adiponectin and HDL-C) and improved lipid profile compared to Glimepiride/metformin therapy.	Vildagliptin	71-83	adiponectin, C1Q and collagen domain containing	Homo sapiens	213-224	
31462933-7	2019	Intragroup analysis showed that vildagliptin reduced insulin, C-peptide and oxidized LDL, and increased adiponectin and glucagon-like peptide-1 while metformin reduced weight, plasma glucose, total cholesterol, HDL-c, LDL-c, and dipeptidyl peptidase-4 activity, with an unexpected increase on tumor necrosis factor-alpha.	Vildagliptin	32-44	adiponectin, C1Q and collagen domain containing	Homo sapiens	104-115	
27881129-9	2016	Compared with placebo, DPP4i (sitagliptin and vildagliptin) treatment significantly elevated adiponectin levels by 0.74 mug/mL (95% confidence interval [CI], 0.45 to 1.03) relative to that using an active-comparison by 0.00 mug/mL (95% CI, -0.57 to 0.56).	Vildagliptin	46-58	adiponectin, C1Q and collagen domain containing	Homo sapiens	93-104	
27881129-10	2016	Compared with active-comparison, vildagliptin treatment increased adiponectin levels by 0.32 mug/mL (95% CI, -0.01 to 0.65), whereas sitagliptin treatment decreased adiponectin levels by -0.24 mug/mL (95% CI, -1.07 to 0.58).	Vildagliptin	33-45	adiponectin, C1Q and collagen domain containing	Homo sapiens	66-77	
27881129-12	2016	CONCLUSIONS: Sitagliptin and vildagliptin increased serum adiponectin levels and had no stronger effect than traditional oral antidiabetic drugs.	Vildagliptin	29-41	adiponectin, C1Q and collagen domain containing	Homo sapiens	58-69	
25802727-9	2015	Vildagliptin increased serum levels of adiponectin, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, whereas liraglutide had no effect on these levels.	Vildagliptin	0-12	adiponectin, C1Q and collagen domain containing	Homo sapiens	39-50	
27048342-8	2016	However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with vildagliptin (WMD: 0.55 mug/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 mug/mL, 95%CI: -1.13, 1.00, p=0.907).	Vildagliptin	112-124	adiponectin, C1Q and collagen domain containing	Homo sapiens	43-54	
27048342-11	2016	CONCLUSION: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin.	Vildagliptin	127-139	adiponectin, C1Q and collagen domain containing	Homo sapiens	68-79	
24824633-9	2014	Adiponectin levels were higher (P = 0.035) and high-sensitivity C-reactive protein levels were lower (P = 0.038) with vildagliptin vs glimepiride.	Vildagliptin	118-130	adiponectin, C1Q and collagen domain containing	Homo sapiens	0-11	
24824633-10	2014	During the oral fat load test, interleukin-6, high-sensitivity C-reactive protein and tumour necrosis factor-alpha peaks were lower and adiponectin peak was higher in the vildagliptin group than in the glimepiride group.	Vildagliptin	171-183	adiponectin, C1Q and collagen domain containing	Homo sapiens	136-147	
20560108-5	2010	Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF-alpha were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin.	Vildagliptin	149-161	adiponectin, C1Q and collagen domain containing	Homo sapiens	94-97	
24137964-7	2013	When vildagliptin was used in combination therapy, with the lean body mass being preserved, there was a statistically significant decrease in total body weight, body mass index (BMI), fat mass, and tissue fat percentage without considering bone mass, as well as waist circumference (WC), which was attended by an elevation of adiponectin levels.	Vildagliptin	5-17	adiponectin, C1Q and collagen domain containing	Homo sapiens	326-337